530 related articles for article (PubMed ID: 9074764)
1. Enteroglucagon.
Holst JJ
Annu Rev Physiol; 1997; 59():257-71. PubMed ID: 9074764
[TBL] [Abstract][Full Text] [Related]
2. Significance of prohormone convertase 2, PC2, mediated initial cleavage at the proglucagon interdomain site, Lys70-Arg71, to generate glucagon.
Dey A; Lipkind GM; Rouillé Y; Norrbom C; Stein J; Zhang C; Carroll R; Steiner DF
Endocrinology; 2005 Feb; 146(2):713-27. PubMed ID: 15528303
[TBL] [Abstract][Full Text] [Related]
3. Proglucagon processing in an islet cell line: effects of PC1 overexpression and PC2 depletion.
Dhanvantari S; Brubaker PL
Endocrinology; 1998 Apr; 139(4):1630-7. PubMed ID: 9528943
[TBL] [Abstract][Full Text] [Related]
4. Is glucagon-like peptide 1 an incretin hormone?
Nauck MA
Diabetologia; 1999 Mar; 42(3):373-9. PubMed ID: 10096792
[TBL] [Abstract][Full Text] [Related]
5. Activation of the hepatic glycine cleavage enzyme system by glucagon and glucagon-related peptides.
Mabrouk GM; Brosnan JT
Can J Physiol Pharmacol; 1997 Sep; 75(9):1096-100. PubMed ID: 9365819
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide.
Stanley S; Wynne K; Bloom S
Am J Physiol Gastrointest Liver Physiol; 2004 May; 286(5):G693-7. PubMed ID: 15068960
[TBL] [Abstract][Full Text] [Related]
7. The physiological role of GLP-1 in human: incretin, ileal brake or more?
Schirra J; Göke B
Regul Pept; 2005 Jun; 128(2):109-15. PubMed ID: 15780430
[TBL] [Abstract][Full Text] [Related]
8. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
Otto Buczkowska E; Dworzecki T
Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
[TBL] [Abstract][Full Text] [Related]
9. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
10. Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1.
Rouillé Y; Kantengwa S; Irminger JC; Halban PA
J Biol Chem; 1997 Dec; 272(52):32810-6. PubMed ID: 9407057
[TBL] [Abstract][Full Text] [Related]
11. Role of prohormone convertases in the tissue-specific processing of proglucagon.
Dhanvantari S; Seidah NG; Brubaker PL
Mol Endocrinol; 1996 Apr; 10(4):342-55. PubMed ID: 8721980
[TBL] [Abstract][Full Text] [Related]
12. Glucagon and glucagon-like peptides 1 and 2.
Holst JJ
Results Probl Cell Differ; 2010; 50():121-35. PubMed ID: 19960378
[TBL] [Abstract][Full Text] [Related]
13. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
Creutzfeldt W
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
[TBL] [Abstract][Full Text] [Related]
14. Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
Sinclair EM; Drucker DJ
Physiology (Bethesda); 2005 Oct; 20():357-65. PubMed ID: 16174875
[TBL] [Abstract][Full Text] [Related]
15. Proglucagon processing in a rat islet cell line resembles phenotype of intestine rather than pancreas.
Philippe J; Mojsov S; Drucker DJ; Habener JF
Endocrinology; 1986 Dec; 119(6):2833-9. PubMed ID: 3536450
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
D'Alessio DA; Vahl TP
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
[TBL] [Abstract][Full Text] [Related]
17. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1.
Ugleholdt R; Zhu X; Deacon CF; Ørskov C; Steiner DF; Holst JJ
Endocrinology; 2004 Mar; 145(3):1349-55. PubMed ID: 14630721
[TBL] [Abstract][Full Text] [Related]
18. Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats.
Fischer KD; Dhanvantari S; Drucker DJ; Brubaker PL
Am J Physiol; 1997 Oct; 273(4):E815-20. PubMed ID: 9357813
[TBL] [Abstract][Full Text] [Related]
19. Central pre-proglucagon derived peptides: opportunities for treatment of obesity.
Larsen PJ; Vrang N; Tang-Christensen M
Curr Pharm Des; 2003; 9(17):1373-82. PubMed ID: 12769729
[TBL] [Abstract][Full Text] [Related]
20. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.
Orskov C; Jeppesen J; Madsbad S; Holst JJ
J Clin Invest; 1991 Feb; 87(2):415-23. PubMed ID: 1991827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
